high dose trivalent inactivated influenza vaccine

The high dose trivalent inactivated influenza vaccine (TIV-HD), marketed as Fluzone High-Dose, is a biologic vaccine developed by Sanofi Pasteur specifically for adults aged 65 years and older. It is an inactivated, split-virus vaccine prepared from influenza viruses propagated in embryonated chicken eggs. Each 0.5 mL dose contains 60 μg of hemagglutinin (HA) antigen for each of the three included influenza strains (two influenza A subtypes and one influenza B type), providing four times the antigen content of standard-dose influenza vaccines. This increased antigen load is intended to overcome the diminished immune response typically seen in the elderly population due to immunosenescence. Clinical trials, including a landmark Phase 4 study, demonstrated that TIV-HD is significantly more effective than standard-dose vaccines in preventing laboratory-confirmed influenza in its target demographic.

Brand names

Fluzone High-Dose

Other names

TIV-HDFluzone HDtrivalent inactivated influenza vaccine high-dose